Indications and uses
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • runny nose • itchy, watery eyes • sneezing • itching of the nose or throat
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • runny nose • itchy, watery eyes • sneezing • itching of the nose or throat
• place 1 tablet on tongue; tablet disintegrates, with or without water adults and children 6 years and over 1 tablet daily; not more than 1 tablet in 24 hours children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor
Loratadine, USP 10 mg
Antihistamine
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
if you have ever had an allergic reaction to this product or any of its ingredients.
liver or kidney disease. Your doctor should determine if you need a different dose.
do not take more than directed. Taking more than directed may cause drowsiness.
an allergic reaction to this product occurs. Seek medical help right away.
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
adults and children 6 years and over | 1 tablet daily; not more than 1 tablet in 24 hours |
children under 6 years of age | ask a doctor |
consumers with liver or kidney disease | ask a doctor |
aspartame, croscarmellose sodium, fruit flavors, magnesium stearate, mannitol, sodium stearyl fumarate
call 1-800-406-7984
Keep the carton. It contains important information.
See end panel for expiration date.
DISTRIBUTED BY
CHAIN DRUG CONSORTIUM
3301 NW BOCA RATON BLVD
SUITE 101, BOCA RATON, FL 33431
Premier Value®
NDC 68016-527-31
Original Prescription Strength
NON-DROWSY*
24 Hour Allergy Relief
Loratadine Orally Disintegrating Tablets, 10 mg
Allergy Relief
Antihistamine
Indoor & Outdoor Allergies
No water needed. Melts in your mouth.
Relief of:
For Adults and Children six years and older!
30 ORALLY DISINTEGRATING TABLETS
COMPARE TO THE ACTIVE INGREDIENT OF CLARITIN®REDITABS®†
*When taken as directed. See Drug Facts Panel.
†This product is not manufactured or distributed by Schering-Plough HealthCare Products, Inc. CLARITIN® and REDITABS® are registered trademarks of Schering Corporation.

| Product concept | Relation | Version | Effective |
|---|---|---|---|
| a62a50ac-1535-4461-9768-8ae703e2e9fb | Product name | 1 | 20210525 |
| 9514609b-a2a9-f8ec-6ba6-3f8e5ee89877 | Product name | 1 | 20140508 |
| bc07ef78-e82d-0c19-31f4-31f263780582 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68016-527-31 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4e7f-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68016-527-31 | Loratadine ODT | 30 in 1 BLISTER PACK | TABLET, ORALLY DISINTEGRATING | 30 | 3 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LORATADINE | ACTIVE INGREDIENT | 7AJO3BO7QN | 3 | |
| LORATADINE | ACTIVE MOIETY | 7AJO3BO7QN | 3 | |
| ASPARTAME | INACTIVE INGREDIENT | Z0H242BBR1 | 3 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | 3 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 3 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 3 | |
| SODIUM STEARYL FUMARATE | INACTIVE INGREDIENT | 7CV7WJK4UI | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68016-527 | 68016-527-31 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LORATADINE | 7AJO3BO7QN | ACTIB |
| ASPARTAME | Z0H242BBR1 | IACT |
| CROSCARMELLOSE SODIUM | M28OL1HH48 | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| MANNITOL | 3OWL53L36A | IACT |
| SODIUM STEARYL FUMARATE | 7CV7WJK4UI | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MANNITOL | MANNITOL | 3OWL53L36A | POWDER / ORAL | 4352 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 616 mg | ||
| SODIUM STEARYL FUMARATE | SODIUM STEARYL FUMARATE | 7CV7WJK4UI | LOZENGE / ORAL | 125 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 64 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | PELLET / ORAL | 24 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION / INTRAVENOUS | 2.5 %w/v | ||
| SODIUM STEARYL FUMARATE | SODIUM STEARYL FUMARATE | 7CV7WJK4UI | TABLET / SUBLINGUAL | 29 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 18 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, FOR SUSPENSION / ORAL | 15 mg | ||
| SODIUM STEARYL FUMARATE | SODIUM STEARYL FUMARATE | 7CV7WJK4UI | GRANULE, FOR SOLUTION / ORAL | 18.2 mg/120ml | ||
| MANNITOL | MANNITOL | 3OWL53L36A | GRANULE, FOR SUSPENSION / ORAL | 6000 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION / INTRAMUSCULAR | 71 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, COATED / ORAL | 224 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | FILM, EXTENDED RELEASE / BUCCAL | 1 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | POWDER, FOR SUSPENSION / ORAL | 420 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | CAPSULE, EXTENDED RELEASE / ORAL | 3 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / INTRAVENOUS | 15400 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | GRANULE, FOR SUSPENSION / ORAL | 420 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TROCHE / ORAL | 50 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, EXTENDED RELEASE / ORAL | 1086 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE, COATED PELLETS / ORAL | 198 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 181 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET / SUBLINGUAL | 495 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| SODIUM STEARYL FUMARATE | SODIUM STEARYL FUMARATE | 7CV7WJK4UI | TABLET, DELAYED RELEASE / ORAL | 216 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, CHEWABLE / ORAL | 195 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING / ORAL | 4364 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / BUCCAL | 17.5 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 113 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE, DELAYED RELEASE / ORAL | 72 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE, DELAYED RELEASE / ORAL | 2043 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE, EXTENDED RELEASE / ORAL | 160 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION / INTRAVENOUS | 15200 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, DELAYED RELEASE / ORAL | 280 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | GRANULE / ORAL | 150 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, EXTENDED RELEASE / ORAL | 173 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | GRANULE, FOR SUSPENSION / ORAL | 282 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | SUSPENSION / ORAL | 23 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 105 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | DROPS / ORAL | NA | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | PELLET / ORAL | 162 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 15400 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION/ DROPS / TOPICAL | 0.3 %w/v | ||
| SODIUM STEARYL FUMARATE | SODIUM STEARYL FUMARATE | 7CV7WJK4UI | TABLET, FOR SUSPENSION / ORAL | 435 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION, CONCENTRATE / INTRAVENOUS | 220 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, DELAYED RELEASE / ORAL | 144 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION / SUBCUTANEOUS | 4.54 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | LOZENGE / ORAL | 20546 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | INJECTION / INTRAMUSCULAR | 1 %w/v | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | POWDER / RESPIRATORY (INHALATION) | 6 mg | ||
| SODIUM STEARYL FUMARATE | SODIUM STEARYL FUMARATE | 7CV7WJK4UI | PELLET / ORAL | 43 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION/ DROPS / OPHTHALMIC | 3.3 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FILM COATED / ORAL | 2309 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | POWDER / ORAL | 63 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | SYRUP / ORAL | 0.63 mg/5ml | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | 200 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A077153-001 | LORATADINE REDIDOSE | LORATADINE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A077153-001 | LORATADINE REDIDOSE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2007-04-11 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ffe62d63-befe-4308-a676-12b3e179a32b | 26a7a473-3b88-4aa6-be56-da315e7556b6 | 2015-10-08 | Warnings | ffe62d63-befe-4308-a676-12b3e179a32b 26a7a473-3b88-4aa6-be56-da315e7556b6 |
Adverse event summaries are temporarily unavailable. Other product information remains available.